News
PLYGF
43.00
NaN%
--
PolyPeptide downgraded to Hold from Buy at Berenberg
TipRanks · 1d ago
Barclays downgrades PolyPeptide Group AG (PPGN) to a Hold
TipRanks · 5d ago
PolyPeptide lifts 2026 outlook after strong H1 surge in peptide demand
TipRanks · 6d ago
Samsung Biologics Moves to Acquire Fast‑Growing Peptide CDMO PolyPeptide
TipRanks · 07/20 00:32
PolyPeptide downgraded to Sector Perform from Outperform at RBC Capital
TipRanks · 07/07 12:05
RBC Capital Sticks to Its Hold Rating for PolyPeptide Group AG (PPGN)
TipRanks · 07/07 06:15
PolyPeptide Group AG (PPGN) Gets a Buy from RBC Capital
TipRanks · 06/23 06:55
PolyPeptide price target raised to CHF 38 from CHF 35 at Berenberg
TipRanks · 06/16 16:17
PolyPeptide price target raised to CHF 40 from CHF 33 at Barclays
TipRanks · 06/16 16:06
Barclays Sticks to Its Buy Rating for PolyPeptide Group AG (PPGN)
TipRanks · 06/16 09:48
UBS Reaffirms Their Buy Rating on PolyPeptide Group AG (PPGN)
TipRanks · 05/07 09:07
Hims & Hers on track to extend gains as RFK Jr. seeks to loosen peptide regulations
Seeking Alpha · 04/16 09:15
FDA sets up AdCom meeting to decide on lifting restrictions on certain peptides
Seeking Alpha · 04/15 17:42
PolyPeptide Confirms Strategic Review Amid Takeover Speculation
TipRanks · 04/14 05:33
Midday Fly By: Goldman reports Q1 beat, Baker Hughes to sell Waygate
TipRanks · 04/13 16:09
PolyPeptide is attracting takeover interest from EQT, KKR, Bloomberg says
TipRanks · 04/13 10:26
RBC Capital Keeps Their Buy Rating on PolyPeptide Group AG (PPGN)
TipRanks · 04/13 10:10
RBC Capital Sticks to Its Buy Rating for PolyPeptide Group AG (PPGN)
TipRanks · 04/10 07:06
PolyPeptide shareholders back all proposals at 2026 AGM
TipRanks · 04/08 16:35
UBS Remains a Buy on PolyPeptide Group AG (PPGN)
TipRanks · 04/07 09:05
More
Webull provides a variety of real-time PLYGF stock news. You can receive the latest news about PolyPeptide Group through multiple platforms. This information may help you make smarter investment decisions.
About PLYGF
Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.